Table 2.
Cost-utility analysis results (per patient)
| Undiscounted | Discounted | |||||
|---|---|---|---|---|---|---|
| LY | QALYs | Costs | LY | QALYs | Costs | |
| Monitoring strategies | ||||||
| [No ACs] | 8.09 | 6.59 | $508,936 | 6.25 | 5.12 | $377,625 |
| [No ACs + POC] | 8.092 | 6.585 | $505,133 | 6.25 | 5.12 | $374,683 |
| [ACs] | 8.113 | 6.606 | $496,208 | 6.26 | 5.13 | $368,370 |
| [ACs + POC] | 8.113 | 6.606 | $492,388 | 6.26 | 5.13 | $365,416 |
| Differences | ||||||
| [ACs] vs [No ACs] | 0.0203 | 0.0212 | − $12,728 | 0.0125 | 0.0137 | − $9255 |
| [No ACs + POC] vs [No ACs] | 0 | 0 | − $3,802 | 0 | 0 | − $2942 |
| [ACs + POC] vs [No ACs] | 0.0203 | 0.0212 | − $16,548 | 0.0125 | 0.0137 | − $12,209 |
| [ACs + POC] vs [ACs] | 0 | 0 | − $3,820 | 0 | 0 | − $2954 |
| ICERs | ||||||
| [ACs] vs [No ACs] | Dominant | Dominant | Dominant | Dominant | ||
| [No ACs + POC] vs [No ACs] | Dominant | Dominant | Dominant | Dominant | ||
| [ACs + POC] vs [No ACs] | Dominant | Dominant | Dominant | Dominant | ||
| [ACs + POC] vs [ACs] | Dominant | Dominant | Dominant | Dominant | ||
Anticoagulation clinic versus no anticoagulation clinic settings with and without POC devices. Costs expressed in local currency (Argentine pesos). Argentina, 2021
AC anticoagulation clinic, ICER incremental cost effectiveness ratio, LY life-year, POC point of care, QALY quality-adjusted life year